{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.57","upperLimit":"49.55","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG000","title":"Arm G (Phase II NF Cohort): Pola+BR in DLBCL"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants in Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment. Values have been rounded off to the nearest whole number.","reportingStatus":"POSTED","timeFrame":"6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)","title":"Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC","type":"SECONDARY","unitOfMeasure":"percentage of participants"}